AMG 714
Pre-clinicalCompleted 1 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedAbout AMG 714
AMG 714 is a pre-clinical stage product being developed by Amgen for Celiac Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT03439475. Target conditions include Celiac Disease.
Hype Score Breakdown
Clinical
3
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03439475 | Pre-clinical | Completed |
| NCT00443326 | Phase 2 | Completed |
| NCT00433875 | Phase 2 | Completed |
Competing Products
17 competing products in Celiac Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| DONQ52 + Placebo | Chugai Pharmaceutical | Phase 1 | 29 |
| Placebo DONQ52 + DONQ52 | Chugai Pharmaceutical | Phase 2 | 42 |
| Placebo + RO5459072 | Roche | Phase 1 | 29 |
| CCX282-B + Placebo | Amgen | Phase 2 | 35 |
| AMG 714 + Placebo | Amgen | Phase 2 | 35 |
| AMG 714 + Placebo | Amgen | Phase 2 | 35 |
| KAN-101 + Placebo | Pfizer | Phase 2 | 35 |
| Cohort 1 in Part A + Cohort 2 in Part A + Group 2 in Part B and Part C + Group 3 in Part B and Part C + Group 4 in Part B and Part C | Pfizer | Phase 1/2 | 24 |
| Ritlecitinib + Placebo | Pfizer | Phase 2 | 42 |
| PRV-015 | Sanofi | Phase 2 | 35 |
| TIMP-GLIA | Takeda Pharmaceutical | Phase 1 | 29 |
| TIMP-GLIA + Placebo | Takeda Pharmaceutical | Phase 2 | 35 |
| PTG-100 + Placebo | Protagonist Therapeutics | Phase 1 | 26 |
| Rifaximin + Placebo | Bausch Health | Pre-clinical | 20 |
| Latiglutenase | Allergy Therapeutics | Phase 2 | 21 |
| BL-7010 + Placebo | BioLineRx | Phase 1/2 | 22 |
| VTP-1000 | Barinthus Biotherapeutics | Phase 1 | 26 |